Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer

Inclusion Criteria: * Clear evidence of metastases to bone on isotope bone scan * Histologically or cytologically confirmed metastatic Estrogen-receptor-positive (ER+) and/or Progesterone-receptor-positive (PR+) and Human Epidermal Growth Factor Receptor (HER) 2 negative breast cancer * Received at least one prior line of hormonal or chemo-therapy for metastatic disease * must be post menopausal * Recovered from toxicities related to prior treatment, except alopecia, lymphopenia, or other non-clinically significant Adverse Events (AEs) * Life expectancy \> 3 months * Adequate organ and marrow function * Sexually active fertile subjects and their partners must agree to use medically accepted methods of contraception * Able to lie flat for up to 45 minutes for imaging studies * Able to swallow capsules or tablets Exclusion Criteria: * Pregnant or breast-feeding * Has experienced clinically-significant hematemesis or hemoptysis of \> 0.5 teaspoons of red blood, or other signs indicative of pulmonary hemorrhage within 3 months before the first dose of study treatment * Untreated, symptomatic or uncontrolled brain metastasis requiring current treatment including steroids and anti-convulsants * more than 1 prior line of chemotherapy for treatment of metastatic breast cancer * prior treatment with fulvestrant * Requires concomitant treatment, in therapeutic doses, with anticoagulants such as warfarin or coumadin-related agents, thrombin or Factor Xa inhibitors, and antiplatelet agents (eg, clopidogrel) * Uncontrolled or significant intercurrent illness * Gastrointestinal disorders, particularly those associated with a high risk of perforation or fistula formation * Active infection requiring systemic treatment * Serious non-healing wound/ulcer/bone fracture * History of organ transplant * Concurrent uncompensated hypothyroidism or thyroid dysfunction * Previously-identified allergy or hypersensitivity to components of the study treatment formulation * Diagnosis of another malignancy, requiring systemic treatment, within the last 2 years, unless non-melanoma skin cancer, in-situ carcinoma of the cervix, or superficial bladder cancer